Inquiry Basket
Loading ......
Filter By Product Search for
HIV Vif
HIV Vif Full Name
Human immunodeficiency virus 1 Vif
HIV Vif Introduction
HIV-1 Vif (viral infectivity factor) is a critical viral accessory protein that counteracts the host's intrinsic immune defense mediated by the APOBEC3 (A3) family of cytidine deaminases. Among these, APOBEC3G (A3G) and APOBEC3F (A3F) are the primary antiviral effectors, capable of inducing G-to-A hypermutations in nascent viral DNA during reverse transcription. Without Vif, these hypermutations can render proviruses nonfunctional and severely impair viral replication. Mechanistically, Vif forms a ternary complex with host factors including Cullin5 (Cul5), elongins B and C (EloB/EloC), and Rbx1, utilizing critical structural motifs such as the HCCH zinc-binding domain and BC-box to recruit the E3 ubiquitin ligase machinery. This complex targets APOBEC3 proteins for proteasomal degradation, thereby preventing their incorporation into virions and maintaining viral infectivity. The degradation pathway has been well-characterized through biochemical and structural studies, demonstrating that mutations in Vif motifs can compromise APOBEC3 antagonism and reduce viral fitness. Importantly, Vif's activity is species- and isoform-specific; while human APOBEC3G and APOBEC3F are efficiently neutralized, orthologs from other primates, such as African green monkeys or rhesus macaques, often resist degradation, illustrating a finely tuned evolutionary interaction between Vif and host restriction factors.
Beyond the canonical targets, APOBEC3 family members exhibit diverse interactions with Vif. APOBEC3H haplotypes, for example, display variable sensitivity: haplotype II is partially resistant to certain Vif variants, whereas haplotype I is more susceptible, highlighting the impact of host genetic variation on viral restriction. Similarly, APOBEC3D and APOBEC3C can exert antiviral activity, but Vif antagonism against these proteins is more variable and context-dependent. APOBEC3F exhibits both deaminase-dependent and deaminase-independent inhibition, whereas APOBEC3G's antiviral activity is largely mediated by its cytidine deaminase function. Polymorphisms, splice variants, and tissue-specific expression levels further modulate sensitivity to Vif, creating a complex landscape of interactions that can influence viral replication, virion composition, and host-virus co-evolution. Cross-species studies indicate that Vif's specificity is shaped by the host APOBEC3 repertoire, with implications for zoonotic barriers and the evolution of viral infectivity.
In vivo studies underscore the functional consequences of Vif–APOBEC3 interplay. In humanized mouse models, APOBEC3 proteins can drive lethal mutagenesis or inhibit reverse transcription in Vif-deficient HIV-1, leading to viral extinction, whereas partial Vif antagonism allows persistence with increased mutational load. APOBEC3 activity can thus act both as a restriction factor and a driver of viral diversification, influencing the evolutionary trajectory of HIV-1. Analyses of patient-derived viral sequences further reveal APOBEC3-mediated mutational footprints, demonstrating that sublethal hypermutation can contribute to sequence diversity while shaping viral adaptation. These observations highlight the nuanced role of Vif in balancing viral replication and immune evasion, and they suggest that therapeutic strategies targeting the Vif–APOBEC3 axis must consider host genetic variation, APOBEC3 isoform sensitivity, and potential for accelerated viral evolution. Collectively, Vif functions as a master regulator of APOBEC3 antagonism, ensuring viral persistence by degrading or excluding cytidine deaminases from virions while shaping both the immediate infectivity and long-term evolutionary dynamics of HIV-1.
Alternate Names for HIV Vif
SOR protein; Virion infectivity factor; VIF
Loading ......
